Deferasirox-d4

• Description :

  Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].

• UNSPSC :

  12352005

• Hazard Statement :

  H315-H319-H335

• Target :

  Bacterial; Ferroptosis; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Anti-infection; Apoptosis; Others

• Field of Research :

  Cancer

• Solubility :

  10 mM in DMSO

• Smiles :

  OC1=C(C=CC=C1)C2=NC(C3=C(C=CC=C3)O)=NN2C4=C([2H])C([2H])=C(C([2H])=C4[2H])C(O)=O

• Molecular Formula :

  C21H11D4N3O4

• Molecular Weight :

  377.39

• Precautions :

  P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30 (3) :638-45.|[3]Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126 (4) :241-5.|[4]Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41 (6) :539-46.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1133425-75-8]